This is the first anti-PD-1 combination approved for patients with persistent, recurrent or metastatic cervical cancer.
Formulary Watch
Latest News
All News
Advertisement
Hikma, which makes the broad-spectrum antibiotic, has experienced manufacturing delays.
The FDA has approved Tavneos, a first-in-class, oral therapy to treat a group of autoimmune diseases characterized by inflammation and damage to small blood vessels.
Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.
Rethmyic is a one-time regenerative tissue-based therapy for children born without a thymus gland.
Drugs with accelerated approval represent a larger amount of Medicaid drug spending relative to their use.
Compared with Keytruda, Libtayo resulted in an incremental gain of 3.44 life-years and incremental cost-effectiveness ratio of $130,329 per quality-adjusted life-year.
The company has received a PDUFA action date of March 11, 2022, for Adlarity, a transdermal patch for the treatment of Alzheimer’s disease.
Inserts replace steroid eyedrops.
Genentech is conducting phase 3 trials of gantenerumab, an anti-amyloid antibody.
Advertisement
Molnupiravir reduced the risk of hospitalization or death by about 50%.
The announcement was made by Pfizer and BioNTech on Twitter
An FDA decision is expected in late 2022.
If approved, maribavir would be the first therapy to treat transplant patients with cytomegalovirus.
Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group
Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.
Blue Plans will now have an additional home delivery option that they can choose to offer their members.
The labeling of Trikafta, which treats cystic fibrosis, has been updated to warn about the possibility of liver failure that could lead to the need for transplantation.
Talicia treats H. pylori infection, a risk factor for stomach cancer; Twirla is a hormonal contraceptive.
Merck plans to seek emergency use authorization for molnupiravir as the first oral treatment for COVID-19.
Three products, including Pfizer’s smoking cessation product Chantix, have been removed because generics are now available.
AstraZeneca’s long-acting antibody combination has been shown to reduce the risk of developing symptomatic infection.
Data show that the vaccine was 94% effective against moderate infection and 100% effective against severe disease.
Tecartus is the first CAR T-cell therapy approved to treat adults with relapsed or refractory ALL.
The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Arpit Patel. Pharm.D., MedImpact
2
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
3
CMS Medicaid Fraud War Room stops more than $203 million in improper payments
4
Mitchell Warren says 3M lenacapavir goal falls short | AIDS 2026
5